Boothbay Fund Management LLC Has $305,000 Stock Holdings in Cencora, Inc. (NYSE:COR)

Boothbay Fund Management LLC trimmed its position in Cencora, Inc. (NYSE:COR - Free Report) by 95.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,359 shares of the company's stock after selling 30,065 shares during the period. Boothbay Fund Management LLC's holdings in Cencora were worth $305,000 as of its most recent filing with the SEC.Top 3 S&P 500 Winners in a Losing MarketOther hedge funds have also added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Cencora during the fourth quarter worth about $1,392,000. Coldstream Capital Management Inc. increased its holdings in Cencora by 3.0% during the fourth quarter. Coldstream Capital Management Inc. now owns 3,399 shares of the company's stock worth $764,000 after buying an additional 100 shares during the last quarter. Hancock Whitney Corp raised its holdings in shares of Cencora by 0.9% in the 4th quarter. Hancock Whitney Corp now owns 75,035 shares of the company's stock valued at $16,859,000 after purchasing an additional 671 shares during the period. Voya Investment Management LLC lifted its position in shares of Cencora by 5.8% in the fourth quarter. Voya Investment Management LLC now owns 310,646 shares of the company's stock valued at $69,796,000 after buying an additional 17,064 shares during the last quarter. Finally, Coppell Advisory Solutions LLC increased its holdings in shares of Cencora by 97.9% in the fourth quarter. Coppell Advisory Solutions LLC now owns 384 shares of the company's stock valued at $86,000 after purchasing an additional 190 shares during the last quarter. Institutional investors own 97.52% of the company's stock. Analyst Ratings ChangesA number of equities analysts recently commented on the stock. UBS Group raised their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday. Wells Fargo & Company upped their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. JPMorgan Chase & Co. upped their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Finally, Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $290.00.Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong BuyView Our Latest Research Report on CencoraCencora Price PerformanceShares of NYSE COR opened at $292.17 on Friday. The firm has a market capitalization of $56.66 billion, a P/E ratio of 41.56, a P/E/G ratio of 1.31 and a beta of 0.55. The firm's 50-day moving average price is $272.65 and its 200-day moving average price is $251.43. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. Teva Pharma is the way to play the re-rise of generic drugs Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year. Cencora Dividend AnnouncementThe firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora's payout ratio is 31.29%. Insider Buying and Selling at CencoraIn related news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,223 shares of company stock worth $13,580,967. Insiders own 10.80% of the company's stock. About Cencora (Free Report)Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.Featured ArticlesFive stocks we like better than CencoraBest of the list of Dividend Aristocrats: Build wealth with the aristocrat indexMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Best Stocks Under $5.00Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousHow is Compound Interest Calculated?Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Cencora Right Now?Before you consider Cencora, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here